Drug profile · INN
insulin glulisine recombinant
APIDRA SOLOSTAR
- US status
- approved
- Patents linked
- 0
- News articles
- 0
Quick answer
insulin glulisine recombinant (APIDRA SOLOSTAR) is an FDA-listed pharmaceutical active ingredient. Route of administration: subcutaneous. Current US regulatory status: approved.
Key facts
INN insulin glulisine recombinant
Brand APIDRA SOLOSTAR
Route SUBCUTANEOUS
Formulation INJECTABLE
Frequently asked questions
What is insulin glulisine recombinant?
insulin glulisine recombinant (APIDRA SOLOSTAR) is an FDA-listed pharmaceutical active ingredient. Route of administration: subcutaneous. Current US regulatory status: approved.
What is the brand name for insulin glulisine recombinant?
APIDRA SOLOSTAR is a marketed brand name for insulin glulisine recombinant. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of insulin glulisine recombinant?
insulin glulisine recombinant has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.